In the United States, the vast majority of oncology care is delivered within community-based centers, yet the most resource-intensive, "next-generation" therapies often remain centralized in academic ...

NCCN upgraded support to category 2A for BCG-unresponsive high-grade papillary Ta/T1 without CIS, while maintaining category ...

New DLBCL trials test bispecifics with chemo, BTK add-ons, and MRD-guided preemptive allo CAR-T to cut relapse risk. The treatment landscape for newly diagnosed diffuse large B-cell lymphoma is on the ...

Results from the phase 3 CLL17 trial (NCT04608318) are helping clarify the ongoing debate over continuous vs fixed-duration therapy in frontline chronic lymphocytic leukemia (CLL) ...

The recent FDA approval of teclistamab (Tecvayli) and daratumumab and hyaluronidase-fihj (Darzelex Faspro) marks a major ...

Severe CRS appeared numerically less frequent than in ZUMA-3, suggesting potential differences in patient selection, supportive care, grading, or real-world mitigation strategies. Tocilizumab and ...

The FDA has granted orphan drug designation (ODD) to a locally delivered formulation of irinotecan (ChemoSeed) for the ...

In this episode of The OncoloGIST, breast cancer oncologist and clinical researcher Dr Paolo Tarantino of Dana-Farber Cancer Institute reflects on how antibody-drug conjugates (AD ...

Lymphoma care still leaves gaps—research aims for higher cure rates, longer remission, and fewer toxicities across B-, T-cell and Hodgkin.

Benefit was maintained across MZL subtypes and subgroups, including splenic MZL, with particularly favorable 24-month outcomes among patients achieving complete response. Safety signals aligned with ...

For oncologists navigating the rapidly evolving landscape of renal cell carcinoma (RCC), the data presented at the 2026 ASCO ...

The updated ASCO living guideline for stage IV driver mutation–negative NSCLC does not offer a single, simple answer, and ...